Recombinant Cedar Virus Chimeras for Safe Henipavirus Vaccine Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective and efficient platforms for developing vaccines, diagnostics, and antiviral drugs against pathogenic henipaviruses like Hendra and Nipah viruses, as existing surrogate systems like Vesicular Stomatitis Virus and retroviruses are difficult to produce in large quantities and have limitations in neutralizing antibody activity.
Innovation Solution
Development of recombinant Cedar virus chimeras that express pathogenic henipavirus proteins, such as F and G glycoproteins, which are replication-competent and can be used to safely study and test vaccines and therapeutic agents against henipaviruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surrogate systems like Vesicular Stomatitis Virus and retroviruses are used to study pathogenic henipaviruses, then research can be conducted without handling BSL-4 viruses, but these systems are difficult to produce in large quantities and have limitations in neutralizing antibody activity
Solution Approach 1:
The patent creates recombinant Cedar virus chimeras that copy the essential pathogenic features of henipaviruses through chimeric F and G glycoproteins, while using the non-pathogenic Cedar virus backbone for safe production. This copying approach enables large-scale production of viral particles that retain neutralizing antibody activity without requiring BSL-4 containment.
Solution Approach 2:
The Cedar virus serves as an intermediary system between non-pathogenic models and actual pathogenic henipaviruses. By expressing chimeric glycoproteins, it mediates the study of pathogenic mechanisms and vaccine development in a BSL-2 setting, bridging the gap between safety and research relevance.
2Measurement precision
If pathogenic henipaviruses like Hendra and Nipah viruses are used directly for vaccine and therapeutic development, then the most accurate immune response can be studied, but this requires BSL-4 containment and poses safety risks
Solution Approach 1:
The patent applies local quality by maintaining the pathogenic glycoprotein components (F and G proteins) while using a non-pathogenic virus backbone. This localized substitution preserves the essential immunogenic features needed for accurate immune response measurement while eliminating the safety risks associated with whole pathogenic virus handling.
Solution Approach 2:
The chimeric glycoproteins copy the critical antigenic determinants of pathogenic henipaviruses, enabling accurate study of neutralizing antibody responses without requiring actual pathogenic virus particles. This copying maintains measurement precision while improving safety.
3Reliability
If recombinant Cedar virus chimeras expressing pathogenic henipavirus proteins are developed, then a safe platform for vaccine testing can be created, but the complexity of generating and characterizing these chimeras increases
Solution Approach 1:
The patent segments the henipavirus genome into functional modules, replacing only the essential F and G glycoprotein genes while retaining the Cedar virus backbone. This segmentation simplifies the engineering process by focusing modifications on specific genomic regions rather than attempting to reconstruct entire pathogenic viruses.
Solution Approach 2:
The Cedar virus backbone serves as a universal platform that can express different chimeric glycoproteins from various henipavirus strains. This multi-functionality allows a single viral platform to be used for studying multiple pathogenic variants, reducing overall system complexity compared to developing separate systems for each virus strain.
Data Source
AI summary
Described herein are replication-competent recombinant Cedar virus chimeras are described that are engineered to express antigenic surface or soluble proteins/polypeptides of a non-CedV henipavirus, such as of a pathogenic henipavirus, such as Nipah virus or Hendra virus. Vaccine compositions containing the recombinant Cedar virus chimeras are also described, as are therapeutic methods and uses for protecting against pathogenic henipavirus infection.